Spondyloarthritis & psoriatic arthritis
Efficacy of Golimumab in Early Axial Spondyloarthritis in Relation to Gut Inflammation: An Early Remission Induction Study
Authors' conclusion
Applying a treat-to-target approach in treatment-naïve early axSpA allows to induce high rates of sustained clinical remission, regardless of the presence of microscopic gut inflammation.
Study context
- Population
- Treatment-naïve patients with axial spondyloarthritis (axSpA) with <1 year of symptom duration and high disease activity
- Participants
- 58 patients
- Exposure
- NSAIDs for 4 weeks, escalation to golimumab 50 mg every 4 weeks if targets not achieved; drug withdrawal upon sustained remission
- Alln = 58
- Outcome
- Sustained clinical remission
Methodological detailssingle-group, treat-to-target, 52-week
- Single-group
- Treat-to-target
- 52-week
Main finding
As reported in the abstract
Patients reaching sustained clinical remission, irrespective of gut inflammation
61.8%
Observational data: associations, not effects.
Further findings
Microscopic gut inflammation at baseline
- Patients with microscopic gut inflammation, predominantly acute
- 28.6%
Escalation of therapy to golimumab required
- Patients requiring escalation to golimumab
- 72.7%
Disease relapse within one year after treatment discontinuation
- Patients relapsing after treatment discontinuation
- 78.1%
Original publication
Efficacy of Golimumab in Early Axial Spondyloarthritis in Relation to Gut Inflammation: An Early Remission Induction Study. Arthritis Rheumatol. Published 11 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →